Sanofi (NASDAQ:SNY) Shares Sold by Central Pacific Bank Trust Division

Central Pacific Bank Trust Division trimmed its stake in Sanofi (NASDAQ:SNY) by 1.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,750 shares of the company’s stock after selling 450 shares during the period. Central Pacific Bank Trust Division’s holdings in Sanofi were worth $1,242,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the business. Stablepoint Partners LLC increased its stake in shares of Sanofi by 0.8% during the third quarter. Stablepoint Partners LLC now owns 23,893 shares of the company’s stock worth $1,377,000 after acquiring an additional 189 shares during the period. PDS Planning Inc grew its holdings in Sanofi by 3.1% in the third quarter. PDS Planning Inc now owns 6,643 shares of the company’s stock valued at $383,000 after purchasing an additional 200 shares during the last quarter. Eagle Ridge Investment Management increased its position in shares of Sanofi by 3.8% in the third quarter. Eagle Ridge Investment Management now owns 5,571 shares of the company’s stock valued at $321,000 after buying an additional 203 shares in the last quarter. Financial Advocates Investment Management raised its stake in shares of Sanofi by 3.4% during the 3rd quarter. Financial Advocates Investment Management now owns 6,327 shares of the company’s stock worth $365,000 after buying an additional 206 shares during the last quarter. Finally, Angeles Investment Advisors LLC boosted its position in shares of Sanofi by 1.9% in the 3rd quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company’s stock worth $653,000 after buying an additional 210 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SNY has been the subject of several research reports. Citigroup upgraded Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Trading Down 0.2 %

NASDAQ SNY traded down $0.10 during mid-day trading on Friday, hitting $48.09. The company’s stock had a trading volume of 943,362 shares, compared to its average volume of 1,090,078. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97. The stock’s fifty day simple moving average is $49.26 and its two-hundred day simple moving average is $52.00. The firm has a market capitalization of $122.04 billion, a P/E ratio of 24.54, a price-to-earnings-growth ratio of 1.23 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $1.35. The firm had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.55 EPS. Research analysts expect that Sanofi will post 4.06 EPS for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.